View from Brussels

Peter O'Donnell is a freelance journalist who specializes in European health affairs and is based in Brussels, Belgium.

Articles

Newly unveiled workplan focuses on harnessing the impact of big data on drug development—and ultimately public health.

The scope of RWE’s use in developing and approving new medicines is pitting key healthcare stakeholders against each other.

Payers join the push for better demonstrations of efficacy of new medicines.

Largely discarded topic beginning to grab hold in policy discussions. 

Battle lines being drawn among key healthcare constituencies, as discussions around new approaches to drug evaluation and decision-making heat up.

The reporting of one man in Europe is changing accountability with compliance.

But despite showing a tightening of focus on clinical trials and evidence, the annual report doesn’t paint the full picture.

EMA’s new release factors in scientific advances, clarity on trial designs.

Just-released analysis by Prescrire contends that the agency “is backtracking on commitments to clinical data transparency.”

EMA continues to familiarize industry with new clinical trial legislation.